RNAZ
TransCode TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
8
U.S. public peers
Grade Position
Below peers
vs peer average
RNAZ vs peer average
30/100
RNAZ vs. peer average (F vs. D)
Grade spread
A 1 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
8 graded
100% of tracked
Peer overview
AARD is the first available peer comparator.
Same sector: Pharmaceuticals, Biotechnology & Life Sciences · Cap $28.45M
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RNAZ
TransCode Therapeutics
AARD
Aardvark Therapeutics
Grade
F
A
Momentum
8
91
Value
41
57
Sentiment
-
67
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs AARD
RNAZ / AARD
Grade Position
Below peers
RNAZ vs. peer average (F vs. D)
30/100
Momentum
8
AARDValue
41
AARDSentiment
-
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RNAZ
AARD is the first peer returned for this comparison set.